Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema

Core Viewpoint - Novo Nordisk has filed for U.S. FDA approval of CagriSema, a once-weekly injection designed to treat obesity by combining two compounds [1] Company Summary - CagriSema represents a new treatment option in the obesity market, potentially expanding Novo Nordisk's portfolio in this growing sector [1] Industry Summary - The obesity treatment market is experiencing significant growth, and the introduction of CagriSema could enhance competition among pharmaceutical companies [1]